Rudy Li
Stock Analyst at Wolfe Research
(4.91)
# 196
Out of 4,685 analysts
81
Total ratings
62.5%
Success rate
79%
Average return
Main Sectors:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $60 | $39.87 | +50.49% | 1 | Aug 26, 2026 | |
| IMUX Immunic | Reiterated: Buy | $30 → $25 | $16.30 | +53.37% | 3 | Aug 11, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $40 | $32.59 | +22.74% | 20 | Aug 3, 2026 | |
| QURE uniQure | Upgraded: Buy | $65 | $49.56 | +31.15% | 2 | Jul 29, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $14.64 | +22.95% | 1 | Jul 7, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $47.89 | -6.03% | 1 | Jul 7, 2026 | |
| SPTX Seaport Therapeutics | Initiated Coverage: Hold | n/a | $26.25 | - | 1 | Jul 7, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $33 | $29.73 | +11.00% | 2 | May 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $160 | $155.92 | +2.62% | 2 | Apr 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $500 | $367.85 | +35.92% | 7 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $48.90 | -7.98% | 2 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 → $60 | $61.93 | -3.12% | 5 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $230 | $206.27 | +11.50% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $25 | $43.82 | -42.95% | 11 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €340.00 | €221.24 | +53.68% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $24.67 | - | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $9.09 | +98.02% | 15 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $36.30 | -58.68% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.5045 | +7,828.64% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $74.54 | n/a | 2 | May 21, 2025 |
Harmony Biosciences Holdings
Aug 26, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $39.87
Upside: +50.49%
Immunic
Aug 11, 2026
Reiterated: Buy
Price Target: $30 → $25
Current: $16.30
Upside: +53.37%
Stoke Therapeutics
Aug 3, 2026
Maintained: Buy
Price Target: $40
Current: $32.59
Upside: +22.74%
uniQure
Jul 29, 2026
Upgraded: Buy
Price Target: $65
Current: $49.56
Upside: +31.15%
COMPASS Pathways
Jul 7, 2026
Maintained: Buy
Price Target: $18
Current: $14.64
Upside: +22.95%
LB Pharmaceuticals
Jul 7, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $47.89
Upside: -6.03%
Seaport Therapeutics
Jul 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $26.25
Upside: -
ACADIA Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $33
Current: $29.73
Upside: +11.00%
Neurocrine Biosciences
Apr 6, 2026
Reiterated: Buy
Price Target: $160
Current: $155.92
Upside: +2.62%
Praxis Precision Medicines
Apr 6, 2026
Maintained: Buy
Price Target: $500
Current: $367.85
Upside: +35.92%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $48.90
Upside: -7.98%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $55 → $60
Current: $61.93
Upside: -3.12%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $230
Current: $206.27
Upside: +11.50%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $43.82
Upside: -42.95%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: €340.00
Current: €221.24
Upside: +53.68%
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $24.67
Upside: -
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $9.09
Upside: +98.02%
Oct 20, 2025
Maintained: Buy
Price Target: $15
Current: $36.30
Upside: -58.68%
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $40
Current: $0.5045
Upside: +7,828.64%
May 21, 2025
Reiterated: Buy
Price Target: $80
Current: $74.54
Upside: n/a